clinical trial · NCT07149363
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Alliance Foundation Trials, LLC.·phase2·recruiting·n = 65
Small Cell Lung Cancer (SCLC)Durvalumab 50 MG/ML
brief summary
This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).
started
Feb 1, 2026
primary completion
Feb 1, 2029
completion
Feb 1, 2031
last updated
Feb 17, 2026
detailed description
This is a phase II open-label, single-arm, multi-center study to evaluate the efficacy and safety of adjuvant immunotherapy with chemotherapy for completely resected pathologic T1-T2, N0-N1, M0 small cell lung cancer (SCLC). The statistical design includes a predefined range of alpha and power to detect an improvement in 2-year disease free survival (DFS).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol